DYNE THERAPEUTICS INC

Dyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference

14 Feb 2024 16:15:16 By Nasdaq GlobeNewswire

Dyne Therapeutics to Present at February Investor Conferences

01 Feb 2024 07:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

11 Jan 2024 16:05:00 By Nasdaq GlobeNewswire

Dyne Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

05 Jan 2024 07:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock

04 Jan 2024 22:46:36 By Nasdaq GlobeNewswire

Dyne Therapeutics Announces Proposed Public Offering of Common Stock

03 Jan 2024 16:25:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Announces Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients Demonstrating Promise of the FORCE™ Platform in Developing Therapeutics for Rare Muscle Diseases

03 Jan 2024 06:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics to Host Virtual Event Tomorrow, January 3 at 8:00 AM ET, to Present Initial Clinical Data from ACHIEVE and DELIVER Trials

02 Jan 2024 16:05:00 By Nasdaq GlobeNewswire

Dyne Therapeutics to Present at November Investor Conferences

07 Nov 2023 07:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Reports Third Quarter 2023 Financial Results and Provides Update on Significant Progress for ACHIEVE and DELIVER Trials and Upcoming Clinical Milestones

30 Oct 2023 07:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics to Present at October Investor Conferences

28 Sep 2023 07:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Receives FDA Orphan Drug Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

20 Sep 2023 16:05:00 By Nasdaq GlobeNewswire

Dyne Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference

05 Sep 2023 07:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

03 Aug 2023 07:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics to Present at Jefferies Healthcare Conference

01 Jun 2023 07:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-101

25 May 2023 07:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics’ Preclinical Data Demonstrating FORCE™ Platform Delivery to CNS Featured in Oral Presentation at ASGCT Annual Meeting

17 May 2023 07:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

11 May 2023 07:30:00 By Nasdaq GlobeNewswire

Dyne Therapeutics to Present at BofA Securities 2023 Healthcare Conference

03 May 2023 07:35:00 By Nasdaq GlobeNewswire

Dyne Therapeutics to Present New Preclinical Data at ASGCT Annual Meeting Demonstrating FORCE™ Platform Delivery to CNS

02 May 2023 16:46:03 By Nasdaq GlobeNewswire